The multiple endocrine neoplasia syndromes

Annual Review of Medicine

Volumn 58, Issue , 2007, Pages 253-265

  Lakhani, Vipul T ^a   You, Y Nancy ^b   Wells, Samuel A ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Germline mutation; Medullary thyroid carcinoma; Menin; RET; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CABERGOLINE; CALCIMIMETIC AGENT; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON; METHIONINE; OCTREOTIDE; PROTEIN RET; PROTON PUMP INHIBITOR; STREPTOZOCIN; VANDETANIB; MEN1 PROTEIN, HUMAN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ALLELE; CANCER GROWTH; CARCINOID; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SURVEILLANCE; ENDOCRINE DISEASE; GASTRINOMA; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PANCREAS ISLET CELL TUMOR; PARATHYROID HYPERPLASIA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; SCREENING; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; GENETICS;

HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; PROTO-ONCOGENE PROTEINS;

EID: 33947496824     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.58.100305.115303     Document Type: Review

References (89)

1. Gagel RFMS. 2003. Multiple endocrine neoplasia. In Williams Textbook of Endocrinology, ed. PR Larsen, HM Kronenberg, S Melmed, et al., pp. 1717-18. St. Louis: Saunders
2. Kouvaraki MA, Shapiro SE, Perrier ND, et al. 2005. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-44
3. Wermer P. 1954. Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16:363-71
4. Brandi ML, Gagel RF, Angeli A, et al. 2001. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86:5658-71
5. Thakker RV. 2000. Multiple endocrine neoplasia type 1. Endocrinol. Metab. Clin. North Am. 29:541-67
6. Trump D, Farren B, Wooding C, et al. 1996. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q. J. Med. 89:653-69
7. Skogseid B, Larsson C, Lindgren PG, et al. 1992. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 75:76-81
8. Duh QY, Hybarger CP, Geist R, et al. 1987. Carcinoids associated with multiple endocrine neoplasia syndromes. Am. J. Surg. 154:142-48
9. Marx SJ, Vinik AI, Santen RJ, et al. 1986. Multiple endocrine neoplasia type I: assessment of laboratory tests to screen for the gene in a large kindred. Medicine 65:226-41
10. O'Halloran DJ, Shalet SM. 1994. A family pedigree exhibiting features of both multiple endocrine neoplasia type 1 and McCune-Albright syndromes. J. Clin. Endocrinol. Metab. 78:523-25
11. Darling TN, Skarulis MC, Steinberg SM, et al. 1997. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch. Dermatol. 133:853-57
12. Marx SJ. 1998. Multiple endocrine neoplasia type 1. In Genetic Basis of Human Cancer, ed. B Vogelstein, KW Kinzler, pp. 489-506. New York: McGraw Hill
13. Benson L, Ljunghall S, Akerstrom G, Oberg K. 1987. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am. J. Med. 82:731-37
14. Vasen HF, Lamers CB, Lips CJ. 1989. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands. Arch. Intern. Med. 149:2717-22
15. Ballard HS FB, Hartstock C. 1964. Familial multiple endocrine adenoma-peptic ulcer complex. Medicine 43:481-515
16. Grama D, Skogseid B, Wilander E, et al. 1992. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J. Surg. 16:611-19
17. Lowney JK, Frisella MM, Lairmore TC, Doherty GM. 1998. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 124:1043-49
18. Yu F, Venzon DJ, Serrano J, et al. 1999. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J. Clin. Oncol. 17:615-30
19. Wolfe MM, Jensen RT. 1987. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N. Engl. J. Med. 317:1200-9
20. Bassett JHD, Williamson C, Pang J, et al. 1997. Glucagonomas in multiple endocrine neoplasia type 1. J. Endocrinol. 152:68
21. Brown CH, Crile GJ. 1964. Pancreatic adenoma with intractable diarrhea, hypokalemia, and hypercalcemia. JAMA 190:30-34
22. Friesen SR, Kimmel JR, Tomita T. 1980. Pancreatic polypeptide as screening marker for pancreatic polypeptide apudomas in multiple endocrinopathies. Am. J. Surg. 139:61-72
23. Skogseid B, Oberg K, Benson L, et al. 1987. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. J. Clin. Endocrinol. Metab. 64:1233-40
24. Asa SL, Singer W, Kovacs K, et al. 1987. Pancreatic endocrine tumor producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome. Acta Endocrinol. 115:331-37
25. Sano T, Asa SL, Kovacs K. 1988. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr. Rev. 9:357-73
26. Sano T, Yamasaki R, Saito H, et al. 1987. Growth hormone-releasing hormone (GHRH)-secreting pancreatic tumor in a patient with multiple endocrine neoplasia type I. Am. J. Surg. Pathol. 11:810-19
27. Farid NR, Buehler S, Russell NA, et al. 1980. Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors. Am. J. Med. 69:874-80
28. Gaitan D, Loosen PT, Orth DN. 1993. Two patients with Cushing's disease in a kindred with multiple endocrine neoplasia type I. J. Clin. Endocrinol. Metab. 76:1580-82
29. Hershon KS, Kelly WA, Shaw CM, et al. 1983. Prolactinomas as part of the multiple endocrine neoplastic syndrome type 1. Am. J. Med. 74:713-20
30. Prosser PR, Karam JH, Townsend JJ, Forsham PH. 1979. Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I. Ann. Intern. Med. 91:41-44
31. Scheithauer BW, Laws ERJ, Kovacs K, et al. 1987. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin. Diagn. Pathol. 4:205-11
32. Williams ED, Celestin LR. 1962. The association of bronchial carcinoid and pluriglandular adenomatosis. Thorax 17:120-27
33. Fisher ER, Hicks J. 1960. Further pathologic observations on the syndrome of peptic ulcer and multiple endocrine tumors. Gastroenterology 38:458-66
34. Rode J, Dhillon AP, Cotton PB, et al. 1987. Carcinoid tumor of stomach and primary hyperparathyroidism: a new association. J. Clin. Pathol. 40:546-51
35. Lee CH, Ching KN, Lui WY, et al. 1986. Carcinoid tumor of the pancreas causing the diarrheogenic syndrome: report of a case combined with multiple endocrine neoplasia, type I. Surgery 99:123-29
36. Teh BT, Zedenius J, Kytola S, et al. 1998. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann. Surg. 228:99-105
37. Teh BT, McArdle J, Chan SP, et al. 1997. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine 76:21-29
38. Bordi C, Falchetti A, Azzoni C, et al. 1997. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am. J. Surg. Pathol. 21:1075-82
39. Skogseid B, Rastad J, Gobl A, et al. 1995. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 118:1077-82
40. Beckers A, Abs R, Willems PJ, et al. 1992. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J. Clin. Endocrinol. Metab. 75:564-70
41. Dluhy RG, Williams GH. 1969. Primary aldosteronism in a hypertensive acromegalic patient. J. Clin. Endocrinol. Metab. 29:1319-24
42. Fertig A, Webley M, Lynn JA 1980. Primary hyperparathyroidism in a patient with Conn's syndrome. Postgrad. Med. J. 56:45-47
43. Burgess JR, Harle RA, Tucker P, et al. 1996. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch. Surg. 131:699-702
44. Snyder N, Scurry MT, Deiss WP. 1972. Five families with multiple endocrine adenomatosis. Ann. Intern. Med. 76:53-58
45. Marx SJ. 2005. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat. Rev. Cancer 5:367-75
46. Bassett JH, Forbes SA, Pannett AA, et al. 1998. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am. J. Hum. Genet. 62:232-44
47. Thakker RV. 1998. Multiple endocrine neoplasia - syndromes of the twentieth century. J. Clin. Endocrinol. Metab. 83:2617-20
48. Marx S, Spiegel AM, Skarulis MC, et al. 1998. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Intern. Med. 129:484-94
49. Metz DCJR, Bale AE, Skarulis MC, Eastman RC, Nieman L, et al. 1994. Multiple endocrine neoplasia type 1: clinical features and management. In The Parathyroids: Basic and Clinical Concepts, ed. JP Bilezikian, R Marcus, MA Levine, pp. 591-646. New York: Raven
50. Tonelli F, Spini S, Tommasi M, et al. 2000. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J. Surg. 24:556-62; discussion 62-63
51. Marx S. 2001. Multiple endocrine neoplasia type 1. In The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, pp. 943-66. New York: McGraw-Hill
52. Rizzoli R, Green J, Marx SJ. 1985. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am. J. Med. 78:467-74
53. Silverberg SJ, Bone HG, Marriott TB, et al. 1997. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. 337:1506-10
54. Norton JA, Fraker DL, Alexander HR, et al. 1999. Surgery to cure the Zollinger-Ellison syndrome. N. Engl. J. Med. 341:635-44
55. Eng C, Clayton D, Schuffenecker I, et al. 1996. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-79
56. Ponder BA. 2001. Multiple endocrine neoplasia type 2. In The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, pp. 931-42. New York: McGraw-Hill
57. Mulligan LM, Kwok JB, Healey CS, et al. 1993. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 363:458-60
58. Carlson KM, Dou S, Chi D, et al. 1994. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA 91:1579-83
59. Donis-Keller H, Dou S, Chi D, et al. 1993. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2:851-56
60. Peczkowska M, Januszewicz A. 2005. Multiple endocrine neoplasia type 2. Fam. Cancer 4:25-36
61. Nunziata V, Giannattasio R, Di Giovanni G, et al. 1989. Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome). Clin. Endocrinol. 30:57-63
62. Donovan DT, Levy ML, Furst EJ, et al. 1989. Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford. Hosp. Med. J. 37:147-50
63. Verdy M, Weber AM, Roy CC, et al. 1982. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J. Pediatr. Gastroenterol. Nutr. 1:603-7
64. Wells SAJ, Baylin SB, Linehan WM, et al. 1978. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann. Surg. 188:139-41
65. Gimm O. 2001. Multiple endocrine neoplasia type 2: clinical aspects. Front. Horm. Res. 28:103-30
66. Vieira AE, Mello MP, Elias LL, et al. 2002. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Horm. Metab. Res. 34:202-6
67. Kebebew E, Ituarte PH, Siperstein AE, et al. 2000. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139-48
68. Machens A, Gimm O, Hinze R, et al. 2001. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J. Clin. Endocrinol. Metab. 86:1104-9
69. Decker RA, Peacock ML, Watson P. 1998. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum. Mol. Genet. 7:129-34
70. Schoder H, Yeung HW. 2004. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin. Nucl. Med. 34:180-97
71. Szakall SJ, Esik O, Bajzik G, et al. 2002. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J. Nucl. Med. 43:66-71
72. Bockisch A, Brandt-Mainz K, Gorges R, et al. 2003. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med. Austriaca 30:22-25
73. Eng C, Mulligan LM, Smith DP, et al. 1995. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin. Endocrinol. 43:123-27
74. Sawka AM, Jaeschke R, Singh RJ, Young WFJ. 2003. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocrinol. Metab. 88:553-58
75. Kudva YC, Sawka AM, Young WFJ. 2003. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J. Clin. Endocrinol. Metab. 88:4533-39
76. Casanova S, Rosenberg-Bourgin M, Farkas D, et al. 1993. Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases. Clin. Endocrinol. 38:531-37
77. Goldstein RE, O'Neill JAJ, Holcomb GW, et al. 1999. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229:755-64; discussion 64-66
78. 18F]Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38:6-8
79. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. 2005. Phaeochromocytoma. Lancet 366:665-75
80. Neumann HP, Bausch B, McWhinney SR, et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346:1459-66
81. You YN, Lakhani V, Wells SAJ. 2006. The multiple endocrine neoplasia syndromes. In The Handbook of Genomic Medicine, ed. W. Hunington, G. Ginsburg. New York: Elsevier. In press
82. Buhr HJ, Kallinowski F, Raue F, et al. 1993. Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. Cancer 72:3685-93
83. Wells SAJ, Chi DD, Toshima K, et al. 1994. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 220:237-47; discussion 47-50
84. Nocera M, Baudin E, Pellegriti G, et al. 2000. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin- streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br. J. Cancer. 83:715-18
85. Brierley J, Tsang R, Simpson WJ, et al. 1996. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305-10
86. Lee JE, Curley SA, Gagel RF, et al. 1996. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120:1064-70; discussion 70-71
87. Skinner MA, Moley JA, Dilley WG, et al. 2005. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 353:1105-13
88. Carlomagno F, Vitagliano D, Guida T, et al. 2002. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:7284-90
89. Wells SAJ, You YN, Lakhani V, et al. 2006. A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Presented at Am. Soc. Clin. Oncol., Atlanta, GA